Emmanuelle E. Bardin

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: An open-label proof-of-concept study.

Real-time breath metabolomics to assess early response to CFTR modulators in adults with cystic fibrosis: An open-label proof-of-concept study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: May 13, 2026

Soft ionization by chemical reaction in transfer-high-resolution mass spectrometry for clinical exhaled breath profiling.

Soft ionization by chemical reaction in transfer-high-resolution mass spectrometry for clinical exhaled breath profiling.

Journal: Analytical and bioanalytical chemistry

Published: February 03, 2026

Treatment perspectives for patients not eligible for therapies for cystic fibrosis

Treatment perspectives for patients not eligible for therapies for cystic fibrosis

Journal: La Revue du praticien

Published: January 23, 2026

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis.

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis.

Journal: Clinical and translational science

Published: March 07, 2025

Short-term modification of breathprint by Elexacaftor/Tezacaftor/Ivacaftor in a paediatric cohort.

Short-term modification of breathprint by Elexacaftor/Tezacaftor/Ivacaftor in a paediatric cohort.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: October 24, 2024

Restored Cytokine-Producing Capacities of Mucosal-associated Invariant T Cells in Pediatric Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor.

Restored Cytokine-Producing Capacities of Mucosal-associated Invariant T Cells in Pediatric Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor.

Journal: American journal of respiratory and critical care medicine

Published: May 17, 2024

Combination of real-time and hyphenated mass spectrometry for improved characterisation of exhaled breath biomarkers in clinical research.

Combination of real-time and hyphenated mass spectrometry for improved characterisation of exhaled breath biomarkers in clinical research.

Journal: Analytical and bioanalytical chemistry

Published: April 14, 2024

Therapeutics in cystic fibrosis: Clinical revolution and new challenges

Therapeutics in cystic fibrosis: Clinical revolution and new challenges

Journal: Medecine sciences : M/S

Published: March 23, 2024

Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.

Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.

Journal: Clinical pharmacokinetics

Published: December 19, 2023

Therapeutic drug monitoring of corticosteroids/β2-agonists in the hair of patients with asthma: an open-label feasibility study.

Therapeutic drug monitoring of corticosteroids/β2-agonists in the hair of patients with asthma: an open-label feasibility study.

Journal: Frontiers in pharmacology

Published: November 16, 2023

A benchmark study of data normalisation methods for PTR-TOF-MS exhaled breath metabolomics.

A benchmark study of data normalisation methods for PTR-TOF-MS exhaled breath metabolomics.

Journal: Journal of breath research

Published: June 23, 2023

Enhanced real-time mass spectrometry breath analysis for the diagnosis of COVID-19.

Enhanced real-time mass spectrometry breath analysis for the diagnosis of COVID-19.

Journal: ERJ open research

Published: March 31, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026